

# Invitation to presentation of Xbrane Biopharma's interim report January – September 2024 on October 24, 2024

**Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, October 24th, 2024, at 13.00 a.m. CET. Xbrane will publish the company's interim report January – September 2024, on Thursday, October 24, 2024, at 8.00 a.m. CET.**

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – September 2024, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

**If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.**

[Xbrane Biopharma Q3 Report 2024 \(financialhearings.com\)](https://financialhearings.com)

**If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.**

[Call Access \(financialhearings.com\)](https://financialhearings.com)

## Contacts

Martin Åmark, CEO  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR  
E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](https://www.xbrane.com)

Press Release  
21 October 2024 08:00:00 CEST

---



## Attachments

---

[Invitation to presentation of Xbrane Biopharma's interim report January – September 2024 on October 24, 2024](#)